The sentinel node. Concepts and clinical applications in neoplasms of the breast and melanoma;El ganglio centinela. Concepto y aplicaciones clínicas en neoplasias de mama y melanoma

Revista Espanola de Medicina Nuclear

Volumn 19, Issue 5, 2000, Pages 371-387

  Fernandez A ^a   Vidal Sicart, Sergi ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN TC 99M; ANTIMONY TECHNETIUM SULFIDE TC 99M; TRACER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST TUMOR; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOSCINTIGRAPHY; MALE; MELANOMA; PARTICLE SIZE; PATIENT SELECTION; RADIATION PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHOGRAPHY; MEDICAL EDUCATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REVIEW; SCINTISCANNING; SKIN TUMOR;

ADULT; AGED; BREAST NEOPLASMS; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOGRAPHY; MALE; MELANOMA; MIDDLE AGED; PATIENT SELECTION; RADIOPHARMACEUTICALS; SKIN NEOPLASMS;

EID: 0034267235     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(00)71895-7     Document Type: Article

References (85)

1. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
2. Cabañas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-66.
3. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and Radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Oncology 1993;2:335-40.
4. Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN. Gamma probe guided lymph node localization in malignant melanoma. Surg Oncol 1993;2:303-8.
5. Alex JC, Krag DN. Gamma probe guided localization of lymph nodes. Oncology 1993;2:137-43.
6. Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH. Lymphoscintigraphy in high risk melanoma of the trunk: Predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993;34:1435-40.
7. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, et al. The orderly progression of melanoma nodal metastases. Am Surg 1994;220:759-67.
8. Thompson JF, McCarthy WH, Bosch CM, O'Brien CJ, Quinn MJ, Paramaesvaran S, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-60.
9. O'Brien CJ, Uren RF, Thompson JF, Howman-Giles RB, Petersen-Schaefer K, Shaw HM, et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg 1995;170:461-6.
10. Krag DN, Meijer S, Weaver DL, Laggie BW, Harlow SP, Tanabe KK, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-8.
11. Albertini JJ, Cruse CW, Rapaport DP, Wells K, Ross M, De Conti R, et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-24.
12. Kapteijn BAE, Nieweg OE, Liem IH, Mooi WJ, Balm AJM, Muller SH, et al. Localizing the sentinel node in cutaneous melanoma: Gamma probe detection versus blue dye. Ann Surg Oncol 1997;4:156-60.
13. Leong SP, Steinmetz I, Habib FA, McMillan A, Gans JZ, Allen RE Jr, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997;132:666-72.
14. Pijpers R, Borgstein PJ, Meijer S, Hoekstra OS, van Hattum LH, Teule GJ. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg 1997;21:788-92.
15. Gogel BM, Kuhn JA, Ferry KM, Fisher TL, Preskitt JT, O'Brien JC, et al. Sentinel lymph node biopsy for melanoma. Am J Surg 1998;176:544-7.
16. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C, et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
17. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early stage melanoma. A multicenter trial. Ann Surg 1999;230:453-65.
18. Statius Muller MG, Borgstein PJ, Pijpers R, van Leeuwen PAM, van Diest PJ, Meijer S. The sentinel node procedure in melanoma patients: failures after follow-up. Eur J Nucl Med 1999;26:S78 (abstract).
19. Vidal-Sicart S, Mateos JJ, Rull R, Vilalta A, Castel T, Palou J, et al. Ganglio centinela en el melanoma maligno. ¿Una técnica consolidada? Rev Esp Med Nucl 2000;19:137 (abstract).
20. Gennari R, Bartolomei M, Testori A, Zurrida S, Stoldt S, Audisio A, et al. Sentinel node localization in primary melanoma: Preoperative dynamic lymphoscintigraphy, intraoperative gammaprobe and vital dye guidance. Surgery 2000;127:19-25.
21. Albertini JJ, Lyman GH, Cox C, Yetaman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patients with breast cancer. JAMA 1996;276:1818-22.
22. Giuliano AE, Jones RC, Brennan M, Statman R: Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
23. Guenther JM, Krishnamoorthy M, Tan RL. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997;3:336-40.
24. Flett MM, Going JJ, Stanton PD, Cooke TG. Sentinel node localization in patients with breast cancer. Brit J Surg 1998;85:991-3.
25. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275-83.
26. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer. A multicenter validation study. N Engl J Med 1998;339:941-6.
27. Crossin JA, Johnson AC, Stewart PB, Turner WW Jr. Gamma-probe-guided resection of the sentinel lymph node in breast cancer. Am Surg 1998;64:666-8.
28. O'Hea BJ, Hill ADK, El-Shirbiny AM, Yeh SDJ, Rosen PP, Coit DG, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423-7.
29. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998;226:645-53.
30. Bass SS, Cox CE, Ku NN, Berman C, Reintgen DS. The role of sentinel lymph node in breast cancer. J Am Coll Surg 1999;189:183-94.
31. Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999;91:368-73.
32. Van der Ent FWC, Kengen RAM, van der Poll HAG, Hoofwijk AGM. Sentinel node biopsy in 70 unselected patients with breast cancer: increased feasibility by using 10 mCi radiocolloid in combination with a blue dye tracer. Eur J Surg Oncol 1999;25:24-9.
33. Fernández A, Benito E, Azpeitia D, Prieto L, Moreno A, Ricart Y, et al. Determinación de la población a estudio y optimización de la técnica de detección linfogammagráfica del ganglio centinela en neoplasias de mama. Rev Esp Med Nucl 2000;19:111 (abstract).
34. Rull M, Fraile M, Julián JM, Fusté F, Vallejos V, Castellà E, et al. Resultados de la biopsia del ganglio centinela en 100 pacientes con cáncer de mama. Rev Senología y Patol Mam 2000;13:16-22.
35. Vera DR, Erik WR, Stadalnik RC. Sentinel node imaging via a non particulate receptor-binding radiotracer. J Nucl Med 1997;38:530-35.
36. Valdés-Olmos RA, Jansen L, Muller SH, Hoefnagel CA, Nieweg O. Aportación de la Medicina Nuclear al estudio del drenaje linfático y la identificación del ganglio linfático centinela en oncología. Rev Esp Med Nucl 1999;18:111-21.
37. Paganelli G, De Cicco C, Cremonesi M, Prisco G, Calza P, Luini A, et al. Optimised sentinel node scintigraphy in breast cancer. Q J Nucl Med 1998;42:49-53.
38. Glass ED, Essner R, Morton DL. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. J Nucl Med 1998;39:1185-90.
39. Vázquez A, Piera C. Coloides en linfogammagrafía: aplicación al ganglio centinela. Rev Esp Med Nucl 1999;18:457-64.
40. Bongers V, Rinkes IHMB, Barneveld PC, Canninga-van Dijk MR, van Rijk PP, van Vloten WA. Towards quality assurance of the sentinel node procedure in malignant melanoma patients. A single institution evaluation and a European survey. Eur J Nucl Med 1999;26:84-90.
41. Wilhelm AJ, Mijnhout GS, Franssen EJF. Radiopharmaceuticals in sentinel lymph-node detection: an overview. Eur J Nucl Med 1999;26(Supl):S36-S42.
42. Keshtgar MRS and Ell PJ. Sentinel lymph node detection and imaging. Eur J Nucl Med 1999;26:57-67.
43. Uren RF, Thompson JF, Howman-Giles R. Sentinel nodes, interval nodes, lymphatic lakes and accurate sentinel node identification. (Carta al director.) Clin Nucl Med 2000;25:234-6.
44. Pijpers R, Meijer S, Hoekstra OS. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m colloidal albumin in breast cancer. J Nucl Med 1997;38:366-8.
45. Schneebaum S, Even-Sapir E, Cohen M, Shacham-Lehrman H, Gat A, Brazovsky E, et al. Clinical applications of gamma-probes: radioguided surgery. Eur J Nucl Med 1999;26(Supl):S26-S35.
46. Tiourina T, Arends B, Huysmans D, Rutten H, Lemaire B, Muller S. Evaluation of surgical gamma probes for radioguided sentinel node localisation. Eur J Nucl Med 1998;25:1224-31.
47. Hoffman EJ, Tornai MP, Janecek M, Patt BE, Iwanczyk JS. Intraoperative probes and imaging probes. Eur J Nucl Med 1999;26:913-35.
48. Zanzonico P, Heller S. The intraoperative gamma probe: Basic principles and choices available. Semin Nucl Med 2000;30:33-48.
49. Krasnow AZ, Hellman RS. Lymphoscintigraphy revisited: 1999. En Freeman LM, ed. Nuclear Medicine Annual 1999. Philadelphia, Lippincott Williams & Wilkins; 1999. p. 17-97.
50. Bostick PJ, Giuliano AE. Vital dyes in sentinel node localization. Semin Nucl Med 2000;30:18-24.
51. Borgstein PJ, Meijer S Pijpers R. Intradermal Blue Dye to identify sentinel lymph node in breast cancer. Lancet 1997;349:1668-9.
52. Essner R, Bostick PJ, Glass EC, Foshag LJ, Haigh PI, Wang HJ, et al. Standardized probe-directed sentinel node dissection in melanoma. Surgery 2000;127:26-31.
53. Van Diest PJ, Peterse HL, Borgstein PJ, Hoekstra O, Meijer CJLM. Pathological examination of sentinel lymph nodes. Eur J Nucl Med 1999;26(Supl):S43-S49.
54. Cochran AJ, Wen DR, Herschman HR. Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int J Cancer 1984;34:159-63.
55. Reintgen DS, Conrad AJ. Detection of occult melanoma cells in sentinel lymph nodes and blood. Semin Oncol 1997;24:S4-S15.
56. Waddington WA, Keshtgar MRS, Taylor I, Lakhani SR, Short MD, Ell PJ. Radiation safety of the sentinel lymph node technique in breast cancer. Eur J Nucl Med 2000;27:377-91.
57. Cochran AJ. The pathologist's role in sentinel lymph node evaluation. Semin Nucl Med 2000;30:11-7.
58. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J Am Acad Dermatol 1996;34:839-47.
59. Parker SL, Tong TT, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
60. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1,001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-5.
61. Kelley JN, Sagebiel RW, Calderón W, Murillo L, Dakin RL, Blois MS. The frequency of local recurrence and microsatellitoses as a guide to re-excision margins for cutaneous malignant melanoma. Ann Surg 1984;200:759-63.
62. Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma: prognostic variables in node positive patients. Ann Surg 1990; 212: 125-131.
63. Soong SJ. Predicting outcome in patients with localized melanoma. En Balch CM, Houghton AN, Sober AJ, Soong SJ. Cutaneous melanoma. St. Louis, Quality Medical; 1998. p. 51-61.
64. Balch CM. The role of elective lymph node dissection in melanoma: Rationale, results and controversies. J Clin Oncol 1988;6:163-72.
65. Cady B. Prophylactic lymph node dissection in melanoma: Does it help? J Clin Oncol 1988;6:2-4 (editorial).
66. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
67. Cascinelli N, Morabito A, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomized trial (WHO melanoma programme). Lancet 1998;351:793-6.
68. Tanabe KK, Reintgen D. The rule of sentinel lymph node mapping for melanoma. Adv Surg 1998;31:79-103.
69. Berman C, Choi J, Hersh MR, Clark RA. Melanoma lymphoscintigraphy and lymphatic mapping. Sem Nucl Med 2000;30:49-55.
70. Bartolomei M, Cremonesi M, Chinol M, De Cicco C, Grana G, Trifiro M, et al. Superiority of lymphoscintigraphy over blue dye technique in the management of primary melanoma of the trunk. Eur J Nucl Med 1999;26:1141 (abstract).
71. Ross MI, Lymphatic mapping and sentinel node biopsy for early stage melanoma: How we do it at the M.D. Anderson Cancer Center. J Surg Oncol 1997;66:273-6.
72. Wells KE, Stadelmann WK, Rapaport DP, Hamlin R, Cruse CW, Reintgen D. Parotid selective lymphadenectomy in malignant melanoma. Ann Plast Surg 1999;43:1-6.
73. Fisher B. The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res 1992;52:2371-83.
74. Fisher B, Redmon C, Poisson R. Eight-year results of a randomised clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-9.
75. Veronesi U, Banfi A, Salvadori B. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer 1990;26:668-70.
76. Early breast cancer trialists' collaborative group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
77. Moore MP, Kinne DW. Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 1997;66:2-6.
78. Silverstein MJ, Gierson ED, Waismann JR. Axillary lymph node disection for T1a breast carcinoma: is it indicated? Cancer 1994;73:664-7.
79. Veronesi U, Paganelli G, Galimberti V, Viale G. Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997;349:1864-7.
80. Ollila W, Brennan MB, Giuliano AE. Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer. Arch Surg 1998;133:647-51.
81. McMasters KM, Giuliano AE, Ross MI, Reintgen DS, Hunt KK, Byrd DR, et al. Sentinel-lymph-node biopsy for breast cancer - Not yet the standard of care. N Engl J Med 1998;339:990-5.
82. Luini A, Pizzamiglio, Paganelli G. L'intervento è radioguidato. Oncologia europea 1999;9:19-25.
83. De Cicco C, Cremonesi M. Luini A, Bartolomei M, Grana Ch, Prisco G. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 1998;39:2080-4.
84. Veronesi U, Luini A, Galimberti V. Extent of metastatic axillary involvement in 1,446 cases of breast cancer. Eur J Surg Oncol 1990;16:127-33.
85. Rosen PR, Lesser ML, Kinner DW, Beattie EJ. Discontinuous or skip metastases in breast cancer. Ann Surg 1983;197:276-83.